SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Morris CD, Einhorn TA 2005 Bisphosphonates in orthopaedic surgery. J Bone Joint Surg Am 87: 16091618.
  • 2
    Michaelson MD, Smith MR 2005 Bisphosphonates for treatment and prevention of bone metastases. J Clin Oncol 23: 82198224.
  • 3
    Nguyen ND, Eisman JA, Nguyen TV 2006 Anti-hip fracture efficacy of bisphosphonates: A Bayesian analysis of clinical trials. J Bone Miner Res 21: 340349.
  • 4
    Rogers MJ 2003 New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des 9: 26432658.
  • 5
    Fisher JE, Rogers MJ, Halasy JM, Luckman SP, Hughes DE, Masarachia PJ, Wesolowski G, Russell RG, Rodan GA, Reszka AA 1999 Alendronate mechanism of action: Geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci USA 96: 133138.
  • 6
    Benford HL, McGowan NW, Helfrich MH, Nuttall ME, Rogers MJ 2001 Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro. Bone 28: 465473.
  • 7
    Sudhoff H, Jung JY, Ebmeyer J, Faddis BT, Hildmann H, Chole RA 2003 Zoledronic acid inhibits osteoclastogenesis in vitro and in a mouse model of inflammatory osteolysis. Ann Otol Rhinol Laryngol 112: 780786.
  • 8
    Rogers MJ, Chilton KM, Coxon FP, Lawry J, Smith MO, Suri S, Russell RG 1996 Bisphosphonates induce apoptosis in mouse macrophage-like cells in vitro by a nitric oxide-independent mechanism. J Bone Miner Res 11: 14821491.
  • 9
    Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman GD, Mundy GR, Boyce BF 1995 Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 10: 14781487.
  • 10
    Colucci S, Minielli V, Zambonin G, Cirulli N, Mori G, Serra M, Patella V, Zambonin Zallone A, Grano M 1998 Alendronate reduces adhesion of human osteoclast-like cells to bone and bone protein-coated surfaces. Calcif Tissue Int 63: 230235.
  • 11
    Boonekamp PM, van der Wee-Pals LJ, van Wijk-van Lennep MM, Thesing CW, Bijvoet OL 1986 Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix. Bone Miner 1: 2739.
  • 12
    Rodan GA, Reszka AA 2002 Bisphosphonate mechanism of action. Curr Mol Med 2: 571577.
  • 13
    van Beek ER, Lowik CW, Papapoulos SE 1997 Effect of alendronate treatment on the osteoclastogenic potential of bone marrow cells in mice. Bone 20: 335340.
  • 14
    Van Beek ER, Lowik CW, Papapoulos SE 2002 Bisphosphonates suppress bone resorption by a direct effect on early osteoclast precursors without affecting the osteoclastogenic capacity of osteogenic cells: The role of protein geranylgeranylation in the action of nitrogen-containing bisphosphonates on osteoclast precursors. Bone 30: 6470.
  • 15
    Nishikawa M, Akatsu T, Katayama Y, Yasutomo Y, Kado S, Kugal N, Yamamoto M, Nagata N 1996 Bisphosphonates act on osteoblastic cells and inhibit osteoclast formation in mouse marrow cultures. Bone 18: 914.
  • 16
    Vitte C, Fleisch H, Guenther HL 1996 Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption. Endocrinology 137: 23242333.
  • 17
    Sauty A, Pecherstorfer M, Zimmer-Roth I, Fioroni P, Juillerat L, Markert M, Ludwig H, Leuenberger P, Burckhardt P, Thiebaud D 1996 Interleukin-6 and tumor necrosis factor alpha levels after bisphosphonates treatment in vitro and in patients with malignancy. Bone 18: 133139.
  • 18
    Schweitzer DH, Oostendorp-van de Ruit M, Van der Pluijm G, Lowik CW, Papapoulos SE 1995 Interleukin-6 and the acute phase response during treatment of patients with Paget's disease with the nitrogen-containing bisphosphonate dimethylaminohydroxypropylidene bisphosphonate. J Bone Miner Res 10: 956962.
  • 19
    Hewitt RE, Lissina A, Green AE, Slay ES, Price DA, Sewell AK 2005 The bisphosphonate acute phase response: Rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins. Clin Exp Immunol 139: 101111.
  • 20
    Thompson K, Rogers MJ 2004 Statins prevent bisphosphonate-induced γ, δ-T-cell proliferation and activation in vitro. J Bone Miner Res 19: 278288.
  • 21
    Mossetti G, Rendina D, De Filippo G, Viceconti R, Di Domenico G, Cioffi M, Postiglione L, Nunziata V 2005 Interleukin-6 and osteoprotegerin systems in Paget's disease of bone: Relationship to risedronate treatment. Bone 36: 549554.
  • 22
    Papadaki HA, Tsatsanis C, Christoforidou A, Malliaraki N, Psyllaki M, Pontikoglou C, Miliaki M, Margioris AN, Eliopoulos GD 2004 Alendronate reduces serum TNFalpha and IL-1beta, increases neutrophil counts, and improves bone mineral density and bone metabolism indices in patients with chronic idiopathic neutropenia (CIN)-associated osteopenia/osteoporosis. J Bone Miner Metab 22: 577587.
  • 23
    Santini D, Fratto ME, Vincenzi B, La Cesa A, Dianzani C, Tonini G 2004 Bisphosphonate effects in cancer and inflammatory diseases: In vitro and in vivo modulation of cytokine activities. BioDrugs 18: 269278.
  • 24
    Gur A, Denli A, Cevik R, Nas K, Karakoc M, Sarac AJ 2003 The effects of alendronate and calcitonin on cytokines in postmenopausal osteoporosis: A 6-month randomized and controlled study. Yonsei Med J 44: 99109.
  • 25
    Dobnig H, Hofbauer LC, Viereck V, Obermayer-Pietsch B, Fahrleitner-Pammer A 2006 Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients. Osteoporos Int 17: 693703.
  • 26
    Kanis JA 1994 Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: Synopsis of a WHO report. WHO Study Group. Osteoporos Int 4: 368381.
  • 27
    D'Amelio P, Grimaldi A, Pescarmona GP, Tamone C, Roato I, Isaia G 2005 Spontaneous osteoclast formation from peripheral blood mononuclear cells in postmenopausal osteoporosis. FASEB J 19: 410412.
  • 28
    Colucci S, Brunetti G, Rizzi R, Zonno A, Mori G, Colaianni G, Del Prete D, Faccio R, Liso A, Capalbo S, Liso V, Zallone A, Grano M 2004 T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: The role of the OPG/TRAIL interaction. Blood 104: 37223730.
  • 29
    Brunetti G, Colucci S, Pignataro P, Coricciati M, Mori G, Cirulli N, Zallone A, Grassi FR, Grano M 2005 T cells support osteoclastogenesis in an in vitro model derived from human periodontitis patients. J Periodontol 76: 16751680.
  • 30
    Brunetti G, Colucci S, Rizzi R, Mori G, Colaianni G, Oranger A, Zallone A, Liso V, Grano M 2006 The role of OPG/TRAIL complex in multiple myeloma: The OPG/TRAIL complex in an in vitro osteoclastogenesis model derived from human multiple myeloma-bone disease. Ann N Y Acad Sci 1068: 334340.
  • 31
    Ramnaraine M, Pan W, Clohisy DR 2006 Osteoclasts direct bystander killing of cancer cells in vitro. Bone 38: 412.
  • 32
    Massey HM, Flanagan AM 1999 Human osteoclasts derive from CD14-positive monocytes. Br J Haematol 106: 167170.
  • 33
    Shalhoub V, Elliott G, Chiu L, Manoukian R, Kelley M, Hawkins N, Davy E, Shimamoto G, Beck J, Kaufman SA, Van G, Scully S, Qi M, Grisanti M, Dunstan C, Boyle WJ, Lacey DL 2000 Characterization of osteoclast precursors in human blood. Br J Haematol 111: 501512.
  • 34
    Faust J, Lacey DL, Hunt P, Burgess TL, Scully S, Van G, Eli A, Qian Y, Shalhoub V 1999 Osteoclast markers accumulate on cells developing from human peripheral blood mononuclear precursors. J Cell Biochem 72: 6780.
  • 35
    Matayoshi A, Brown C, DiPersio JF, Haug J, Abu-Amer Y, Liapis H, Kuestner R, Pacifici R 1996 Human blood-mobilized hematopoietic precursors differentiate into osteoclasts in the absence of stromal cells. Proc Natl Acad Sci USA 93: 1078510790.
  • 36
    Roato I, Grano M, Brunetti G, Colucci S, Mussa A, Bertetto O, Ferracini R 2005 Mechanisms of spontaneous osteoclastogenesis in cancer with bone involvement. FASEB J 19: 228230.
  • 37
    Clavel G, Bessis N, Boissier MC 2003 Recent data on the role for angiogenesis in rheumatoid arthritis. Joint Bone Spine 70: 321326.
  • 38
    Van Valckenborgh E, De Raeve H, Devy L, Blacher S, Munaut C, Noel A, Van Marck E, Van Riet I, Van Camp B, Vanderkerken K 2002 Murine 5T multiple myeloma cells induce angiogenesis in vitro and in vivo. Br J Cancer 86: 796802.
  • 39
    Athanasou NA, Sabokbar A 1999 Human osteoclast ontogeny and pathological bone resorption. Histol Histopathol 14: 635647.
  • 40
    Rodan GA, Martin TJ 1982 Role of osteoblasts in hormonal control of bone resorption - a hypothesis. Calcif Tissue Int 34: 311.
  • 41
    Sahni M, Guenther HL, Fleisch H, Collin P, Martin TJ 1993 Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J Clin Invest 91: 20042011.
  • 42
    Hofbauer LC, Kuhne CA, Viereck V 2004 The OPG/RANKL/RANK system in metabolic bone diseases. J Musculoskelet Neuronal Interact 4: 268275.
  • 43
    Pan B, Farrugia AN, To LB, Findlay DM, Green J, Lynch K, Zannettino AC 2004 The nitrogen-containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activating TNF-alpha converting enzyme (TACE). J Bone Miner Res 19: 147154.
  • 44
    Wang XM, Yu SF, Yang ZP 2000 Apoptosis of osteoclast-like cells induced by alendronate is related to Fas gene expression. Chin J Dent Res 3: 2632.
  • 45
    Moreau MF, Guillet C, Massin P, Chevalier S, Gascan H, Basle MF, Chappard D 2007 Comparative effects of five bisphosphonates on apoptosis of macrophage cells in vitro. Biochem Pharmacol 73: 718723.